CHICAGO – July 15, 2021 – First Analysis acted as the exclusive financial advisor to Kno2 for its $15 million Series A funding round. Kno2 enables interoperability at scale across every patient care setting with the capability to send, receive, find and use patient information with everyone. The funding round was led by Health Enterprise Partners (HEP) and Providence Ventures.
The new funding will enable Kno2 to accelerate continued expansion of connectivity and workflows across the platform while growing the breadth and depth of the partner base integrated with the company’s APIs. It will also enable Kno2 to expand its reach to underserved markets such as small to medium physician offices, post-acute and behavioral health providers, community services, and more – connecting these critical participants to the rest of the healthcare ecosystem.
“Healthcare has become disillusioned with interoperability,” said Jon Elwell, CEO of Kno2. “For years, we have watched rounds of legislation, billions of dollars in investment, and a multitude of predictions that soon we were going to wake up to an entirely connected ecosystem. Unfortunately, the opposite has been true, but Kno2 is changing this reality.” Elwell continued, “Through our unique approach which incorporates not only our technology but also our partnership and economic models, we are disrupting the status quo and ensuring connectedness and meaningful exchange are a reality for all, from the smallest to the largest participant.”
“Prior to this round, all of our fundraising was self-directed. Having learned the importance of finding the right investment partner to support our vision, we knew it would be critical to start with the right advisor to navigate our alternatives. We were fortunate to have such a great partner like First Analysis lead us through this process – they really made a difference in telling our story and their experience and professionalism directly influenced our successful outcome.”
First Analysis focuses its advisory services on high-growth, entrepreneur-driven companies like Kno2. The First Analysis team worked closely with the management team to optimally position the company and find the best partner to help Kno2 to continue to achieve its growth objectives. First Analysis was actively engaged throughout the transaction process, including preparation, positioning, investor coordination and contact, due diligence, and negotiation.
Kno2 connects all participants across the care continuum, human or technology, for the secure, effortless, and maximized exchange of patient information. Serving as healthcare’s largest network aggregator, Kno2’s patented API technology provides connectivity and exchange across every major national network, a growing number of regional networks such as HIEs, cloud fax, proprietary platforms that drive critical workflows, and continued expansion of EHR integrations. A technology vendor no longer has to be concerned with the heavy lift of connecting to each network and can stay focused to its core business and application, driving the best user experience possible within their technology. This is what it means to be Kno2 Connected.
About First Analysis
Founded in 1981, First Analysis has a 40-year track record of serving emerging growth companies and established industry leaders within its focused areas of domain expertise. Our investment banking practice leverages industry insights developed through our research and investing activities to deliver value to clients across the life cycle of a business. Providing senior-level attention to every client, First Analysis offers superior execution across a comprehensive range of investment banking services, including M&A advisory and growth financings.
To download a pdf version of this press release, please follow the link below:
First Analysis acted as the exclusive financial advisor to Kno2 for its $15 million Series A funding co-led by Providence Ventures and Health Enterprise Partners
First Analysis Securities Corp. (FASC) is a registered broker/dealer with FINRA and member SIPC.